This content is viewable by members only. Visit MY ACCOUNT on the top menu to log in or to register for a 30 day free trial or purchase a subscription for UV Reporter 1 Year Single Membership or UV Reporter 1 Year Group Membership - $189 for first member and $25 for each additional member.
Aytu BioPharma Announces Publication of Data Demonstrating Ultraviolet-A Light Reduces Cellular Cytokine Release from Human Endotracheal Cells Infected with Coronavirus
Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced today that data from a laboratory study evaluating the ultraviolet A light used in the Healight™ endotracheal catheter technology was published in the peer reviewed journal Photodiagnosis and Photodynamics Therapy. “These latest in vitro findings continue to build upon the body of scientific evidence supporting the potential of this UVA platform technology and may help to explain the observed effects of Healight in SARS-CoV-2. These findings point to the fact that UVA light demonstrated a statistically significant effect on several key secreted cytokines and…
Published in Informational
More from InformationalMore posts in Informational »
- Congressman Sanford D. Bishop Jr. Presents Federally Funded Check to Leesburg, GA to Include UV Wastewater Treatment
- Westmoreland, PA Approves $31 M in Water Treatment Plant Upgrades Including Ultraviolet Disinfection System
- Bioaerosol Chamber Disinfected with Ultraviolet Light Between Studies
- Morro’s Bay, CA Has $160M Water Treatment Online Ahead of Schedule and Includes UV Advanced Oxidation
- PURO UV, Ushio and Johnson Controls Join Forces to Further the Scientific Research of Far UV-C and Validate its Benefits to IAQ